A Study to Evaluate How the Body Processes 14C-VX-993 After a Single Oral Dose
Completed · Phase 1
Conditions studied: Pain
In brief
The purpose of the study is to evaluate the routes and rate of elimination and recovery of total radioactivity (TRA) and characterize the Pharmacokinetic (PK) of VX-993 after a single oral dose of 14C-VX-993.
Key facts
- Study ID
- NCT06886269
- Run by
- Vertex Pharmaceuticals Incorporated
- People needed
- 8
- Starts
- 2025-03-21
- Expected to finish
- 2025-05-17
- Last updated by the study team
- 2025-06-18
Who can join
Age: 18 and older, up to 55. Sex: male. Healthy volunteers: accepted.
Where it is running
- Celerion - Lincoln — Lincoln, Nebraska, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.